David Endicott joins the board with a background in navigating corporate spin-offs, having led Alcon’s transition to a standalone public company starting in 2018. His experience spans over 25 years at Allergan and leadership roles at Hospira Infusion Systems. Within MiniMed, he will serve on the Compensation and Talent Committee. CEO Que Dallara cited Endicott’s history of scaling global healthcare businesses as a critical asset for the firm’s current growth phase.
In section Releases
MiniMed Expands Board With Alcon CEO David Endicott and Linnea Burman
Diabetes technology firm MiniMed has expanded its board from nine to 11 members, appointing Alcon CEO David Endicott and Medtronic executive Linnea Burman. The additions arrive as the Northridge-based company seeks to solidify its operational independence following its recent public market separation from Medtronic.
Linnea Burman, currently the Senior Vice President and President of Neurovascular at Medtronic, joins as a board designee following Medtronic’s decision to remain the majority shareholder after MiniMed’s IPO. Burman brings nearly two decades of tenure at Medtronic, including experience in cranial and spinal technologies. These appointments reflect a strategic push to bolster MiniMed’s governance as it focuses on its integrated insulin delivery ecosystem across 80 countries.
Comments (0)
No comments yet. Be the first!